Health
FDA approves first treatment for a rare genetic disorder – News-Medical.Net
Today, the U.S. Food and Drug Administration approved Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria type 1 (PH1), a rare genetic disorder.
Reviewed by Emily Henderson, B.Sc.Nov 23 2020
Today, the U.S. Food and Drug Administration approved Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria type 1 (PH1), a rare genetic disorder. This approval is a cumulation of the work of experts and community members coordinated by the Oxalosis & Hyperoxaluria Foundation and the Kidney Health Initiative.
The approval of Oxlumo represents a great triumph of community involvement to address a rare disease. It is a result of input…
-
General17 hours agoFerries and celebrities as pollies dash to win the west
-
Noosa News22 hours agoCSIRO, winemakers pair to breed mildew, climate-resistant grapevines
-
Noosa News18 hours agoChild killer Rick Thorburn who murdered Tiahleigh Palmer found dead in jail cell
-
Business22 hours ago3 ASX 200 stocks I’d buy and hold for the next 10 years